Abstract
Among women in the Thames Cancer Registry database with a first breast cancer diagnosed between 1961–1995 observed numbers of subsequent cancers were compared with expected numbers and standardized incidence ratios were calculated. The occurrence of breast cancers subsequent to cancers at other sites was also examined. Women diagnosed with breast cancer before age 50 had significantly elevated risks for 9 cancer sites namely, oesophagus, stomach, lung, bone, connective tissue, breast, corpus uteri, ovary and myeloid leukaemia compared with 2 sites (corpus uteri and myeloid leukaemia) in women diagnosed at age 50 and above. Some of these associations are consistent with the effects of known inherited cancer susceptibility genes, shared environmental factors, or therapy. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adami HO, Bergkvist L, Krusemo U and Persson I (1984) Breast cancer as a risk factor for other primary malignant diseases. A nationwide cohort study. J Natl Cancer Inst 73: 1049–1055
Andersson M, Storm HH and Mouridsen T (1991) Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83: 1013–1017
Bevan S and Houlston RS (1999) Genetic predisposition to gastric cancers. QJM 92: 5–10
Boice JD, Land CE, Preston DL, (1996) Ionizing radiation. In: Cancer Epidemiology and Prevention. 2nd ed, Schottenfeld D, Fraumeni JF (ed), pp 319–354. Oxford University Press: New York
Breast Cancer Linkage Consortium (1999) Cancer Risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310–1316
De Vivo I, Gertig DM, Nagase S, Hankinson SE, O’Brien R, Speizer FE, Parsons R and Hunter DJ (2000) Novel germline mutations in the PTEN tumour suppressor found in women with multiple cancers. J Med Genet 37: 336–341
Easton DF, Ford D and Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1 mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265–271
Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Survey 25: 101–124
Ewertz M and Mouridsen HT (1985) Second cancer following cancer of the female breast in Denmark, 1943–80. Natl Cancer Inst Monogr 68: 325–329
Fitzgerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ and Haber DA (1997) Heterozygous ATM mutations do not contribute to early onset breast cancer. Nat Genet 15: 307–310
Ford D, Easton DF, Bishop DT, Narod SA and Goldgar DE (1994) Risks of cancer in BRCA1 mutation carriers: Breast Cancer Linkage Consortium. Lancet 343: 692–695
Freihoff D, Kempe A, Beste B, Wappenschmidt B, Kreyer E, Hayashi Y, Meindl A, Krebs D, Wiestler OD, von Deimling A and Schmutzler RK (1999) Exclusion of a major role for the PTEN tumour suppressor gene in breast carcinomas. Br J Cancer 79: 754–758
Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K and Vogel V (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91: 1829–1846
Harvey EB and Brinton LA (1985) Second cancer following cancer of the breast in Connecticut. (1935–1982). Natl Cancer Inst Monogr 68: 99–109
Henderson BE, Pike MC, Bernstein L, Ross RK, (1996) Breast cancer. In: Cancer Epidemiology and Prevention. 2nd ed, Schottenfeld D, Fraumeni JF (ed), pp 1022–1039. Oxford University Press: New York
Houlston RS and Stratton MR (1995) Genetics of non-medullary thyroid cancer. QJM 88: 685–693
Inskip HM, Kinlen LJ, Taylor AM, Woods CG and Arlett CF (1999) Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br J Cancer 79: 1304–1307
Kollmannsberger C, Hartmann JT, Kanz L and Bokemeyer C (1998) Risk of secondary myeloid leukaemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 124: 207–214
Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C and Parsons R (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16: 64–67
Palmer JR and Rosenberg L (1993) Cigarette smoking and the risk of breast cancer. Epidemiol Rev 15: 145–156
Peto J, Easton DF, Matthews FE, Ford D and Swerdlow AJ (1996) Cancer mortality in relatives of women with breast cancer: the OPCS study. Int J Cancer 65: 275–283
Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J and Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91: 943–949
Prior P and Waterhouse JA (1981) Multiple primary cancers of the breast and ovary. Br J Cancer 44: 628–636
Ron E, Curtis R, Hoffman DA and Flannery JT (1984) Multiple primary breast and thyroid cancer. Br J Cancer 49: 87–92
Schimke RN (1984) Genetic aspects of multiple endocrine neoplasia. Ann Rev Med 35: 25–31
Schottenfeld D (1996) Multiple primary cancer. In: Cancer Epidemiology and Prevention. 2nd ed, Schottenfeld D and Fraumeni JF (eds), pp 1370–1387. Oxford University Press: New York
Scotto J, Fears TR, Kraemer KH and Fraumeni JF (1996) Nonmelanoma skin cancer. In: Cancer Epidemiology and Prevention. 2nd ed, Schottenfeld D Fraumeni JF (eds) pp 319–354. Oxford University Press: New York
StataCorp (1999). Stata Statistical Software: Release 6.0. Stata Corporation: College Station
Swift M, Reitnauer PJ, Morrell D and Chase CL (1987) Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 316: 1289–1294
Teppo L, Pukkala E and Saxen E (1985) Multiple cancer – an epidemiological exercise in Finland. J Natl Cancer Inst 75: 207–217
Vassilopoulou-Sellin R, Palmer L, Taylor S and Cooksley CS (1999) Incidence of breast carcinoma in women with thyroid carcinoma. Cancer 85: 696–705
Volk N and Pompe-Kirn V (1997) Second primary cancers in breast cancer patients in Slovenia. Cancer Causes and Control 8: 764–770
Warren W, Eeles RA, Ponder BA, Easton DF, Averill D, Ponder MA, Anderson K, Evans AM, DeMars R and Love R (1992) No evidence of germline mutations in exons 5–9 of the p53 gene in 25 breast cancer families. Oncogene 7: 1043–1046
World Health Organisation (1992). International Statistical Classification of Diseases and Related Health Problems, Tenth Revision. WHO: Geneva
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Evans, H., Lewis, C., Robinson, D. et al. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. Br J Cancer 84, 435–440 (2001). https://doi.org/10.1054/bjoc.2000.1603
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1603
Keywords
This article is cited by
-
Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis
Breast Cancer Research (2023)
-
Should the BCRA1/2-mutations healthy carriers be valid candidates for hematopoietic stem cell donation?
Hereditary Cancer in Clinical Practice (2021)
-
Clinicopathological features, survival and risk in breast cancer survivors with thyroid cancer: an analysis of the SEER database
BMC Public Health (2019)
-
Review of the possible association between thyroid and breast carcinoma
World Journal of Surgical Oncology (2018)
-
Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer
Breast Cancer Research and Treatment (2018)